Gapping up
In reaction to earnings/guidance:
- GBX +4.7%, LEVI +2.9%, PSMT +2.4%, ACCD +2.2%, MATX +1.8%, ASX +1% (Q2 revs), IMOS +0.7% (Q2 revs), TSM +0.5% (Q2 revs)
Other news:
- STMP +35.5% (to be acquired by Thoma Bravo for $6.6 bln in cash, STMP shareholders to receive $330/share)
- LMPX +16.9% (stock repurchase and dividend approval contingent on debt refinancing)
- HGEN +12.1% (receives acceptance of Marketing Authorization for lenzilumab in COVID-19 by MHRA in UK)
- GLUE +10.2% (Versant Venture Capital discloses 15.3% stake)
- IBIO +5.8% (adds three anti-cancer targets to pipeline; enters into research services agreement with FairJourney Biologics)
- BNTX +4.1% (PFE and BNTX developing COVID-19 booster shot to target delta variant, according to CNBC)
- BLUE +3.4% (announces positive recommendation by PRAC regarding article 20 safety referral review of ZYNTEGLO gene therapy for transfusion-dependent ß-thalassemia and marketing to resume in EU)
- CRUS +2.1% (to acquire Lion Semiconductor for $335 mln)
- NFE +2.1% (signs framework agreement with Sri Lanka to construct offshore LNG terminal)
- BLDP +1.9% (receives purchase order for fuel cell modules to power 15 Tata Motors buses)
- CYCN +1.4% (CYCN and Beacon Biosignals announce expanded partnership)
- JKS +1.3% (signed a strategic cooperation agreement with Maersk Shipping)
- MAPS +1.1% (stock offering)
- COST +1% (reports June adjusted comps of +7.9%)
- BA +1% (China could begin 737 MAX flight tests, according to Bloomberg)
- PM +1% (to acquire Vectura Group for $1.2 bln)
Analyst comments:
- NOV +3.9% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- DB +3.2% (upgraded to Sector Perform from Underperform at RBC Capital Mkts)
- NSC +2.3% (upgraded to Outperform from In-line at Evercore ISI)
- DFS +2.2% (upgraded to Buy from Neutral at Citigroup)
- TEX +2.1% (upgraded to Buy from Hold at Deutsche Bank)